Ford goes ‘under the hood’ of healthcare outreach
WHAT IT MEANS AND WHY IT’S IMPORTANT — It’s often said that yesterday’s science fiction is tomorrow’s reality, and while automakers have yet to unveil flying cars similar to the ones in “Blade Runner,” the integration of WellDoc’s services with Ford Motor’s SYNC technology serves as a prime example.
(THE NEWS: Ford developing health care in the dashboard. For the full story, click here.)
Among developed countries, the United States is one of the most car-dependent. Given the amount of time that Americans spend in their cars and the sedentary lifestyles associated with car dependence, bringing together health and transportation — two of humanity’s most basic needs — is a natural extension to the overall trend of health and technology companies creating ways for patients to store and share health information with technology devices, a trend that until now mostly was limited to smartphone applications and computers.
And the opportunities that such innovations as Ford’s create for retail pharmacies almost are too numerous to calculate. With the popularity of drive-through pharmacies across the country and new services like Walgreens’ charging stations for electric cars, retail pharmacies are in an ideal position to bring health care on wheels rolling toward them.
Edurant OKed as HIV treatment by FDA
SILVER SPRING, Md. — The Food and Drug Administration has approved a new antiretroviral treatment for HIV made by Johnson & Johnson, the agency said Friday.
The FDA approved J&J subsidiary Tibotec Therapeutics’ Edurant (rilpivirine) as a treatment for use in combination with other HIV drugs in adults who have not been treated before.
“Patients may respond differently to various HIV drugs or experience varied side effects,” FDA Office of Antimicrobial Products director Edward Cox said. “FDA’s approval of Edurant provides an additional treatment option for patients who are starting HIV therapy.”
The drug belongs to a class known as non-nucleoside reverse transcriptase inhibitors, or NNRTIs, and is designed for use as part of a highly active antiretroviral therapy, or HAART, regimen.
FDA committee recommends approval of Abbott’s Trilipix, statin combination
ABBOTT PARK, Ill. — A Food and Drug Administration advisory committee has voted to recommend that the FDA retain approval of an Abbott drug for high cholesterol in combination with a statin.
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee met Thursday to discuss whether to recommend continued FDA approval of Trilipix (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia and a high risk of heart disease. The FDA is not bound by advisory committee votes, but usually follows them.
Results from the “ACCORD Lipid” study had raised concerns about the safety and efficacy of combining the drug with a statin, showing no significant difference between patients treated with Trilipix and simvastatin versus those treated with placebo and simvastatin, and an analysis of the data indicated that women who took the combination experienced more heart attacks than those in the placebo group, but the clinical significance of the finding was unclear at the time.
“Abbott appreciates the committee’s recognition that the totality of data, including ‘ACCORD Lipid,’ supports retaining the co-administration indication for Trilipix in appropriate patients,” Abbott VP global pharmaceutical clinical development Eugene Sun said. “We also appreciate the request for more clinical data and look forward to further discussions with the FDA.”